DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...
Rarer diabetes patients in Singapore can now receive up to 80% government subsidies for continuous glucose monitoring (CGM) ...
IEEE Spectrum on MSN
Why the most accurate glucose monitors are failing some users
In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings. The recall affects approximately 3 million sensors and was caused by an ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Patients with type 2 diabetes demonstrated improved glycemic control with the use of automated insulin delivery regardless of baseline C-peptide levels. Automated insulin delivery (AID) systems should ...
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...
Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...
Numerous comments on a Facebook group called “Dexcom G7 – Issues and Complaints” has brought to light a problem that users are referring to as “goose necking.” MD+DI learned more about this issue – ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
Dexcom, a glucose-monitoring company based in San Diego, is laying off 350 employees. The company announced Wednesday that it was cutting 3% of its global workforce. Of the 350 laid off, 196 workers ...
Dexcom has rebounded since my last update, but I maintain a 'Hold' rating due to continued overvaluation and limited upside potential. Growth remains solid, especially in sensors and U.S. expansion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback